newsfilter
← Latest News
GlobeNewswire·

Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates

BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS)